Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W. Schnittger S, et al. Among authors: loffler h. Blood. 2002 Jul 1;100(1):59-66. doi: 10.1182/blood.v100.1.59. Blood. 2002. PMID: 12070009 Free article.
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, Kern W, Löffler H, Hiddemann W. Schoch C, et al. Among authors: loffler h. Genes Chromosomes Cancer. 2002 Sep;35(1):20-9. doi: 10.1002/gcc.10088. Genes Chromosomes Cancer. 2002. PMID: 12203786
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.
Schoch C, Haase D, Fonatsch C, Haferlach T, Löffler H, Schlegelberger B, Hossfeld DK, Becher R, Sauerland MC, Heinecke A, Wörmann B, Büchner T, Hiddemann W. Schoch C, et al. Among authors: loffler h. Br J Haematol. 1997 Dec;99(3):605-11. doi: 10.1046/j.1365-2141.1997.4473257.x. Br J Haematol. 1997. PMID: 9401073 Free article.
Cell lineage specific involvement in acute promyelocytic leukaemia (APL) using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques for the detection of the translocation t(15;17)(q22;q12).
Haferlach T, Löffler H, Nickenig C, Ramm-Petersen L, Meeder M, Schoch R, Schlegelberger B, Schnittger S, Schoch C, Hiddemann W. Haferlach T, et al. Among authors: loffler h. Br J Haematol. 1998 Oct;103(1):93-9. doi: 10.1046/j.1365-2141.1998.00959.x. Br J Haematol. 1998. PMID: 9792295 Free article.
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
Schoch C, Haferlach T, Haase D, Fonatsch C, Löffler H, Schlegelberger B, Staib P, Sauerland MC, Heinecke A, Büchner T, Hiddemann W; German AML Cooperative Study Group. Schoch C, et al. Among authors: loffler h. Br J Haematol. 2001 Jan;112(1):118-26. doi: 10.1046/j.1365-2141.2001.02511.x. Br J Haematol. 2001. PMID: 11167792 Free article. Clinical Trial.
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W. Kern W, et al. Among authors: loffler h. Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28. Blood. 2003. PMID: 12393605 Free article. Clinical Trial.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: loffler h. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
507 results